ReviewViruses2014
Options and obstacles for designing a universal influenza vaccine.
Review in Viruses, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- A systematic review and meta-analysis of cross-reactivity of antibodies induced by H7 influenza vaccine.Human vaccines & immunotherapeutics · 2020Pooled it
- Article
- Article
- Filling two needs with one deed: a combinatory mucosal vaccine against influenza A virus and respiratory syncytial virus.Frontiers in immunology · 2024Article
- Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG.Pharmaceutics · 2023Article
- Review
- Cross-protective immunity of the haemagglutinin stalk domain presented on the surface ofVirulence · 2021Article
- Furin cleavage sites naturally occur in coronaviruses.Stem cell research · 2021Article
- A Host-Restricted Self-Attenuated Influenza Virus Provides Broad Pan-Influenza A Protection in a Mouse Model.Frontiers in immunology · 2021Article
- Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development.Frontiers in immunology · 2021Article
- Review
- Built-in RNA-mediated chaperone (chaperna) for antigen folding tailored to immunized hosts.Biotechnology and bioengineering · 2020Article
- Review
- Public Health-Driven Research and Innovation for Next-Generation Influenza Vaccines, European Union.Emerging infectious diseases · 2019Article
- The Quest for a Truly Universal Influenza Vaccine.Frontiers in cellular and infection microbiology · 2019Review
- Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo.American journal of epidemiology · 2018Review
- Eliciting unnatural immune responses by activating cryptic epitopes in viral antigens.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018Article
- Towards the Application of Human Defensins as Antivirals.Biomolecules & therapeutics · 2018Review
- Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Investigating Different Mechanisms of Action in Combination Therapy for Influenza.Frontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the discovery of antibodies specific to a highly conserved stalk region of the influenza virus hemagglutinin (HA), eliciting such antibodies has been considered the key to developing a universal influenza vaccine that confers broad-spectrum protection against various influenza subtypes. To achieve this goal, a prime/boost immunization strategy has been heralded to redirect host immune responses from the variable globular head domain to the conserved stalk domain of HA. While this approach has been successful in eliciting cross-reactive antibodies against the HA stalk domain, protective efficacy remains relatively poor due to the low immunogenicity of the domain, and the cross-reactivity was only within the same group, rather than among different groups. Additionally, concerns are raised on the possibility of vaccine-associated enhancement of viral infection and whether multiple boost immunization protocols would be considered practical from a clinical standpoint. Live attenuated vaccine hitherto remains unexplored, but is expected to serve as an alternative approach, considering its superior cross-reactivity. This review summarizes recent advancements in the HA stalk-based universal influenza vaccines, discusses the pros and cons of these approaches with respect to the potentially beneficial and harmful effects of neutralizing and non-neutralizing antibodies, and suggests future guidelines towards the design of a truly protective universal influenza vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.